ARK Invest Rotates Into Biotech, Cuts Software Stakes in Latest Daily Trades

Overview

• On Feb. 18, ARK bought 1,251,270 shares of Recursion Pharmaceuticals for about $4.33 million and added 37,075 CRISPR Therapeutics shares valued at roughly $1.97 million.
• Same day sells included 566,650 PagerDuty shares for about $3.89 million, 11,366 Teradyne shares for roughly $3.47 million, and 103,218 DraftKings shares for about $2.33 million.
• ARK also reduced 18,162 Twist Bioscience shares for nearly $960,000 and 7,662 Salesforce shares for about $1.41 million, extending cuts to consumer and software names.
• The Feb. 17 filing showed buys of roughly $8 million in Broadcom, $6.1 million in AMD, and $6.9 million in Coinbase, alongside the day’s largest move: a $13.3 million Teradyne sale.
• ARK’s Feb. 17 activity also included a $6.3 million Twist Bioscience sell after a licensing-driven rally, trims in Airbnb, Pinterest, and PagerDuty, and about $4.5 million added to CRISPR Therapeutics; AMD weakness and a Coinbase target cut were notable market backdrops.